Doximity
DOCS
$24.01
+3.63%
Doximity, Inc. operates a cloud-based digital platform exclusively for U.S. medical professionals, providing tools for collaboration, secure patient care coordination, virtual visits, medical news, and career management within the Healthcare Information Services industry. The company is the dominant network for American physicians, establishing itself as a critical platform with a near-monopoly reach in its niche, which drives a highly profitable, asset-light software-as-a-service (SaaS) business model. The current investor narrative is sharply divided between viewing the stock as a deep-value opportunity following a severe price collapse and concerns over growth deceleration, as recent quarterly revenue growth of 9.8% year-over-year marks a significant slowdown from prior periods, raising debates about its future growth trajectory and market saturation.…
DOCS
Doximity
$24.01
Related headlines
Investment Opinion: Should I buy DOCS Today?
Rating & Thesis: Doximity is a Hold with a Speculative Buy bias for risk-tolerant investors. The core thesis is that the stock presents a compelling asymmetric bet where the downside appears limited by a strong financial foundation, but the upside is contingent on a uncertain growth re-acceleration. Analyst sentiment is mixed but leans cautiously optimistic, with several firms maintaining 'Overweight' ratings, suggesting a base of institutional support at these levels.
Supporting Evidence: The Hold rating is supported by four key data points. First, the forward P/E of 14.81x is reasonable for a profitable SaaS company if the $2.41 EPS estimate is achieved. Second, the company's exceptional gross margin of 89.89% and net margin of 33.27% demonstrate a best-in-class business model. Third, the pristine balance sheet (D/E of 0.011) and strong FCF generation provide a significant margin of safety. Fourth, the stock's extreme oversold condition, trading just 17% above its 52-week low, suggests most bad news is priced in.
Risks & Conditions: The two biggest risks are the persistence of single-digit revenue growth and further multiple compression from the current elevated trailing P/E. This Hold would upgrade to a Buy if quarterly revenue growth re-accelerates to 15%+ YoY or if the forward P/E compresses below 12x without a deterioration in fundamentals. It would downgrade to a Sell if revenue growth decelerates further below 5% or if the stock breaks decisively below its $20.55 support level on high volume. On balance, the stock is fairly valued to slightly undervalued based on forward earnings potential, but remains overvalued on a trailing basis, requiring growth to validate the current price.
Sign up to view all
DOCS 12-Month Price Forecast
The AI assessment is Neutral with Medium confidence. Doximity is a high-quality business caught in a painful transition from hyper-growth to maturity. The severe price decline has likely priced in the current growth slowdown, creating a potential value opportunity, but the lack of a visible catalyst for re-acceleration keeps the near-term outlook murky. The stellar financials prevent a Bearish stance, while the growth uncertainty prevents a full Bullish call. The stance would upgrade to Bullish on evidence of sustained revenue growth re-acceleration above 12% for two consecutive quarters. It would downgrade to Bearish if revenue growth falls below 5% or if the key $20.55 support level is broken on a fundamental deterioration.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Doximity's 12-month outlook, with a consensus price target around $31.21 and implied upside of +30.0% versus the current price.
Average Target
$31.21
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$19 - $31
Analyst target range
Analyst coverage for Doximity is active, with recent ratings from multiple major firms, though a precise consensus count and average target price are not available in the provided data. The institutional ratings show a mixed but leaning-positive sentiment, with recent actions including maintains of 'Overweight' from Piper Sandler, Morgan Stanley, and Barclays, an upgrade to 'Buy' from Canaccord Genuity, and maintains of 'Neutral' from JP Morgan, Mizuho, and Goldman Sachs, indicating a cautious optimism among bulls. The wide dispersion in analyst views—ranging from 'Neutral' to 'Overweight'—signals high uncertainty regarding the company's near-term trajectory, with high targets likely pricing in a successful growth re-acceleration and margin stability, while lower or neutral ratings may reflect concerns over the sustainability of its growth rates and competitive positioning in a slower environment.
Bulls vs Bears: DOCS Investment Factors
The investment debate for Doximity is sharply polarized between its exceptional fundamental quality and its severe growth deceleration. Currently, the bear case holds stronger near-term evidence, as the dramatic slowdown to 9.8% revenue growth is a concrete, deteriorating trend that directly challenges the premium valuation the market has historically awarded the stock. However, the bull case is supported by a bedrock of profitability, cash flow, and balance sheet strength that is rare for a company trading near its 52-week lows. The single most important tension in this thesis is whether the current growth rate represents a temporary trough or a permanent step-down to a mature, slower-growth phase. The resolution of this question—specifically, the trajectory of revenue growth over the next 2-3 quarters—will determine if the stock is a deep-value opportunity or a value trap.
Bullish
- Exceptional Profitability & Cash Flow: Doximity generates an exceptionally high gross margin of 89.89% and a robust net margin of 33.27%, which are hallmarks of a superior SaaS business model. The company also produces substantial free cash flow, with TTM FCF of $311.55 million, providing significant financial flexibility for share repurchases and growth investments without needing debt.
- Dominant, Asset-Light Market Position: The company operates a near-monopoly digital platform for U.S. medical professionals, creating a powerful network effect and a highly defensible moat. This dominant position within a critical niche supports a recurring subscription model that drives 95% of revenue, creating a predictable and scalable revenue stream.
- Strong Balance Sheet & Financial Health: Doximity has a fortress-like balance sheet with a negligible debt-to-equity ratio of 0.011 and a strong current ratio of 6.97. This financial strength provides a significant margin of safety and allows the company to weather economic downturns or invest counter-cyclically while peers may struggle.
- Compelling Forward Valuation: The stock's forward P/E of 14.81x, based on analyst EPS estimates of $2.41, represents a significant discount to its trailing P/E of 48.58x and appears reasonable for a profitable, high-margin SaaS company. This forward multiple suggests the market has already priced in substantial pessimism regarding future growth.
Bearish
- Severe Growth Deceleration: The most critical bear argument is the dramatic slowdown in revenue growth to just 9.8% YoY in the latest quarter, down sharply from prior high-teens and twenties growth rates. This deceleration raises legitimate concerns about market saturation and the company's ability to re-accelerate its top-line expansion.
- Premium Valuation Despite Slowdown: Despite the growth slowdown, the stock still trades at a premium trailing P/E of 48.58x and a Price-to-Sales ratio of 19.01x. These multiples remain elevated relative to sector averages and the company's own historical range, creating significant valuation compression risk if growth does not re-accelerate.
- Persistent Negative Momentum & Underperformance: The stock has shown persistent negative momentum, down 40.91% over the last three months and severely underperforming the S&P 500 by -44.5 percentage points over the same period. This technical weakness suggests institutional selling and a lack of buyer conviction, which can become a self-fulfilling prophecy.
- High Revenue Concentration Risk: The company's revenue is overwhelmingly concentrated in its Subscription segment, which constituted 95% of total last quarter revenue ($175.38M of $185.05M). This lack of diversification makes the company highly vulnerable to any disruption in its core platform monetization or competitive incursions.
DOCS Technical Analysis
The prevailing price trend is a severe and sustained downtrend, with the stock down 57.35% over the past year and 64.08% over the last six months. With a current price of $24.01, it is trading just 17% above its 52-week low of $20.55 and 69% below its 52-week high of $76.51, positioning it deep in oversold territory and suggesting either a profound value opportunity or a fundamental breakdown that the market is pricing in. Recent short-term momentum shows continued weakness, with the stock down 40.91% over the last three months and 0.70% over the past month, indicating the downtrend remains intact despite a minor monthly pullback; this persistent negative momentum starkly contrasts with the S&P 500's positive returns over the same periods, highlighting severe relative underperformance. Key technical support is firmly established at the 52-week low of $20.55, while major resistance lies at the 52-week high of $76.51; a breakdown below $20.55 could trigger another leg down, whereas a sustained move above it might signal a basing process. The stock's beta of 1.419 confirms it is approximately 42% more volatile than the broader market, which amplifies both downside risk and potential upside during a recovery, a critical factor for risk-aware position sizing.
Beta
1.42
1.42x market volatility
Max Drawdown
-72.0%
Largest decline past year
52-Week Range
$21-$77
Price range past year
Annual Return
-57.3%
Cumulative gain past year
| Period | DOCS Return | S&P 500 |
|---|---|---|
| 1m | -0.7% | +12.6% |
| 3m | -40.9% | +3.1% |
| 6m | -64.1% | +3.9% |
| 1y | -57.3% | +29.7% |
| ytd | -44.5% | +4.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DOCS Fundamental Analysis
Revenue growth has decelerated markedly, with the most recent quarterly revenue of $185.05 million representing a 9.8% year-over-year increase, a sharp slowdown from the high-teens and twenties growth rates seen in prior comparable quarters. The Subscription segment, constituting $175.38 million or 95% of total revenue, is the core driver, while the Service and Other segment contributed only $9.67 million, indicating the company's heavy reliance on its flagship platform monetization. The company remains highly profitable with a net income of $61.56 million in the last quarter and an exceptional gross margin of 89.89%, though the net margin of 33.27% and operating margin of 38.85% have compressed slightly from peaks above 40% seen in previous quarters, suggesting some operating leverage challenges amid slower growth. Doximity exhibits exceptional financial health, with a robust balance sheet evidenced by a negligible debt-to-equity ratio of 0.011, a strong current ratio of 6.97, and substantial free cash flow generation, with TTM free cash flow of $311.55 million providing ample internal funding for growth initiatives and share repurchases without reliance on external financing.
Quarterly Revenue
$185053000.0B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.89%
Latest Quarter
Free Cash Flow
$311547000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DOCS Overvalued?
Given the company's positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio is elevated at 48.58x, while the forward PE is significantly lower at 14.81x; this wide gap implies the market is pricing in a substantial recovery in earnings growth expectations for the coming year, likely tied to analyst EPS estimates averaging $2.41. Compared to sector averages, the trailing PE of 48.58x is at a significant premium, though the forward multiple of 14.81x appears more reasonable if the projected earnings growth materializes; the Price-to-Sales ratio of 19.01x also remains high, reflecting the market's continued premium for the company's exceptional profitability profile despite growth concerns. Historically, the current trailing PE of 48.58x sits well above the stock's own historical range observed in recent quarters, which has typically fluctuated between the high 20s and low 60s; trading near the upper end of this band suggests the market is still attributing a premium multiple, possibly awaiting confirmation of a growth re-acceleration to justify current levels.
PE
48.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 27x~112x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
44.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Doximity's primary financial risk is its heavy reliance on a single revenue stream, with the Subscription segment constituting 95% of total sales. While the company boasts a net margin of 33.27% and robust free cash flow generation ($311.55M TTM), the recent compression from peaks above 40% indicates operating leverage is turning negative as growth slows. Furthermore, the elevated trailing P/E of 48.58x creates earnings multiple compression risk; if the company fails to meet the forward EPS estimate of $2.41 that justifies the lower 14.81x forward multiple, the stock could face another significant de-rating.
Market & Competitive Risks: The stock faces substantial market risk due to its premium valuation (P/S of 19.01x) amidst a growth slowdown, making it vulnerable to sector-wide rotation out of high-multiple software stocks. Its beta of 1.419 confirms it is 42% more volatile than the market, amplifying both upside and downside moves. While its near-monopoly in physician networking provides a strong moat, the risk lies in disruptive technologies or new entrants that could fragment its user base or pressure pricing power in its core subscription offerings.
Worst-Case Scenario: The worst-case scenario involves the confirmation of permanent growth stagnation. This would unfold as the next two quarterly earnings reports show revenue growth remaining in the single digits or decelerating further, triggering a wave of analyst downgrades from their current cautious 'Neutral' and 'Overweight' stances. Combined with a broader market sell-off in tech, this could lead to a full de-rating towards the stock's 52-week low of $20.55, representing a downside of approximately -14% from the current price of $24.01. A breach of that key technical support could see the stock test levels last seen at its IPO, implying a total peak-to-trough loss approaching the -71.98% max drawdown already experienced.
FAQ
The key risks, ranked by severity, are: 1) Growth Stagnation: Revenue growth has decelerated sharply to 9.8% YoY, raising saturation concerns. 2) Valuation Compression: The high trailing P/E of 48.58x is vulnerable to de-rating if growth does not rebound. 3) Market Volatility: With a beta of 1.42, the stock is 42% more volatile than the market, amplifying losses in downturns. 4) Concentration Risk: 95% of revenue comes from a single subscription segment, lacking diversification. Any disruption to this core business would have an outsized impact.
The 12-month forecast is bifurcated, with a 50% probability Base Case target range of $28-$35, a 30% probability Bull Case of $45-$55, and a 20% probability Bear Case of $20-$24. The Base Case, which is most likely, assumes revenue growth stabilizes around 10% and the company meets the $2.41 EPS estimate, supporting a forward P/E in the mid-teens. The forecast is highly dependent on the next few quarterly earnings reports, which will determine if the growth deceleration has bottomed or is set to continue.
DOCS presents a mixed valuation picture. On a trailing basis, it appears overvalued with a P/E of 48.58x and a P/S of 19.01x, which are premiums to sector averages. However, on a forward-looking basis, it appears fairly valued to slightly undervalued, with a forward P/E of 14.81x based on analyst EPS estimates of $2.41. This wide gap implies the market is paying a fair price for expected future earnings growth but a premium for past performance. The valuation ultimately hinges on whether the company can meet or exceed those forward earnings estimates, making it a bet on growth stabilization.
DOCS is a speculative buy for investors with a high risk tolerance and a long-term horizon. The stock offers a compelling risk/reward setup, trading just 17% above its 52-week low with a reasonable forward P/E of 14.81x, backed by exceptional profitability and zero debt. However, it is not a good buy for conservative investors, as the single biggest risk is the severe deceleration in revenue growth to 9.8% YoY. It becomes a good buy if you believe the company's dominant network position will allow it to stabilize and eventually re-accelerate growth, making it a classic "fallen angel" opportunity.
DOCS is unsuitable for short-term trading due to its high volatility (beta 1.42) and lack of near-term positive catalysts. It is best considered a long-term investment with a minimum holding period of 2-3 years. This timeframe allows for the company's growth initiatives to potentially bear fruit and for the market to recognize the underlying value of its profitable, asset-light model. The stock pays no dividend, so the entire return is dependent on capital appreciation, which requires patience as the growth narrative potentially resets.